119 related articles for article (PubMed ID: 31631810)
1. Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events.
Ailawadhi S; Medhekar R; Princic N; Fowler R; Tran O; Bhowmik D; Panjabi S
J Oncol Pharm Pract; 2020 Jul; 26(5):1070-1079. PubMed ID: 31631810
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients.
Zhong Y; Valderrama A; Yao J; Donga P; Bilir P; Neumann PJ
Value Health; 2018 Mar; 21(3):304-309. PubMed ID: 29566837
[TBL] [Abstract][Full Text] [Related]
4. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
Nash Smyth E; Conti I; Wooldridge JE; Bowman L; Li L; Nelson DR; Ball DE
J Med Econ; 2016; 19(5):477-86. PubMed ID: 26671598
[TBL] [Abstract][Full Text] [Related]
5. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
Barlev A; Song X; Ivanov B; Setty V; Chung K
J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
7. Health resource utilization associated with skeletal-related events: results from a retrospective European study.
Body JJ; Pereira J; Sleeboom H; Maniadakis N; Terpos E; Acklin YP; Finek J; Gunther O; Hechmati G; Mossman T; Costa L; Rogowski W; Nahi H; von Moos R
Eur J Health Econ; 2016 Jul; 17(6):711-21. PubMed ID: 26253584
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational study.
Ashcroft J; Duran I; Hoefeler H; Lorusso V; Lueftner D; Campioni M; Intorcia M; Bahl A
Eur J Haematol; 2018 May; 100(5):479-487. PubMed ID: 29444353
[TBL] [Abstract][Full Text] [Related]
9. Canadian health care institution resource utilization resulting from skeletal-related events.
Habib MJ; Merali T; Mills A; Uon V
Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.
Hagiwara M; Delea TE; Saville MW; Chung K
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events.
Hardtstock F; Kocaata Z; Wilke T; Dittmar A; Ghiani M; Belozeroff V; Harrison DJ; Maywald U; Tesch H
Eur J Health Econ; 2021 Mar; 22(2):243-254. PubMed ID: 33459901
[TBL] [Abstract][Full Text] [Related]
13. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer.
Delea TE; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Thorac Oncol; 2006 Jul; 1(6):571-6. PubMed ID: 17409919
[TBL] [Abstract][Full Text] [Related]
14. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.
Hechmati G; Cure S; Gouépo A; Hoefeler H; Lorusso V; Lüftner D; Duran I; Garzon-Rodriguez C; Ashcroft J; Wei R; Ghelani P; Bahl A
J Med Econ; 2013; 16(5):691-700. PubMed ID: 23441975
[TBL] [Abstract][Full Text] [Related]
15. Cost of skeletal complications from bone metastases in six European countries.
Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
[TBL] [Abstract][Full Text] [Related]
16. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
17. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
Hagiwara M; Delea TE; Chung K
J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
[TBL] [Abstract][Full Text] [Related]
18. Short-term disability in solid tumor patients with bone metastases and skeletal-related events.
Qian Y; Song X; Zhang K; Balakumaran A; Arellano J
J Med Econ; 2015 Mar; 18(3):210-8. PubMed ID: 25426582
[TBL] [Abstract][Full Text] [Related]
19. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone.
Hagiwara M; Panjabi S; Sharma A; Delea TE
J Med Econ; 2019 Aug; 22(8):818-829. PubMed ID: 31046501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
